Biomarker Analysis in Bo21015, a Phase Ii Randomised Study of First-Line Bevacizumab (Bev) Combined with Carboplatin-Gemcitabine (Cg) or Carboplatin-Paclitaxel (Cp) in Patients (Pts) with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer (Nscl

內科YU, CHONG-JENCHONG-JENYU2012-07-052018-07-112012-07-052018-07-112011http://ntur.lib.ntu.edu.tw//handle/246246/240645en-US[SDGs]SDG3Biomarker Analysis in Bo21015, a Phase Ii Randomised Study of First-Line Bevacizumab (Bev) Combined with Carboplatin-Gemcitabine (Cg) or Carboplatin-Paclitaxel (Cp) in Patients (Pts) with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer (Nscl